Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis.

× No keyword cloud information.

7 in total

1. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.

Authors: C Efthymiopoulos; S L Bramer; A Maroli
Journal: Clin Pharmacokinet Date: 1997 Impact factor: 6.447

2. Synthesis and biological properties of substituted 1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acids.

Authors: H Miyamoto; H Yamashita; H Ueda; H Tamaoka; K Ohmori; K Nakagawa
Journal: Bioorg Med Chem Date: 1995-12 Impact factor: 3.641

3. Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.

Authors: G A Pankuch; M R Jacobs; P C Appelbaum
Journal: J Antimicrob Chemother Date: 1995-01 Impact factor: 5.790

4. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.

Authors: M J Bale; R N Jones; M E Erwin
Journal: Diagn Microbiol Infect Dis Date: 1994-05 Impact factor: 2.803

5. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.

Authors: P J Cook; J M Andrews; R Wise; D Honeybourne; H Moudgil
Journal: J Antimicrob Chemother Date: 1995-02 Impact factor: 5.790

6. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.

Authors: T Imada; S Miyazaki; M Nishida; K Yamaguchi; S Goto
Journal: Antimicrob Agents Chemother Date: 1992-03 Impact factor: 5.191

7. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.

Authors: H Wakebe; T Imada; H Yoneda; F Mukai; K Ohguro; K Ohmori; H Tamaoka; Y Yabuuchi
Journal: Antimicrob Agents Chemother Date: 1994-10 Impact factor: 5.191

7 in total

1 in total

1. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

Authors: Sheila Malay; Patricia M Roblin; Tamara Reznik; Andrei Kutlin; Margaret R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 2002-02 Impact factor: 5.191

1 in total